DR. DOUGLAS E FAIG M.D.
Prescription History 1053340521
Internal Medicine - Hematology & Oncology in Ft Lauderdale, FL


Quality Rating: 81.31 out of 100 score

NPI Status: Active since June 30, 2006

Contact Information

5700 N FEDERAL HWY
SUITE 5
FT LAUDERDALE, FL
ZIP 33308
Phone: (954) 776-1800
Fax: (954) 776-3647

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DOUGLAS E FAIG M.D., an active Hematology & Oncology specialist practicing in Ft Lauderdale, FL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 62 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 22 claims alone.

Medication Index

No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 42.0
Days Supply 1,260
FL State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills135.7
Peer Average Days Supply4,055
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.5% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $224.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.04

State Avg Cost Per Claim

$24.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 23.0
Days Supply 690
FL State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills130.4
Peer Average Days Supply3,717
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.2% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,170.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$598.65

State Avg Cost Per Claim

$852.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 30.6
Days Supply 901
FL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills65.6
Peer Average Days Supply1,944
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.9% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $402.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.86

State Avg Cost Per Claim

$39.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Temazepam

Generic Formulation: TemazepamSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
FL State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills65.5
Peer Average Days Supply1,934
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.0% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $139.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.65

State Avg Cost Per Claim

$11.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.

Therapeutic Applications

This medication is used to treat a certain sleep problem (insomnia). It may help you fall asleep faster, stay asleep longer, and lessen how often you wake up during the night, so you can get a better night's rest. Temazepam belongs to a class of drugs called benzodiazepines. It acts on your brain to produce a calming effect. Use of this medication is usually limited to short treatment periods of 1 to 2 weeks or less. If your insomnia continues for a longer time, talk to your doctor to see if you need other treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DOUGLAS E FAIG M.D. provides transparency into local medical care patterns within Ft Lauderdale, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.